Leave Your Message

Submit An Free Inquiry

Our medical team will make an evaluation for you, based on the information you provided. This procedure is free of charge.

AI Helps Write
AI Helps Write

Sabuwar Fata a Maganin Ciwon Daji: Maganin TILs Ya Fito A Matsayin Gaba

2024-06-05

Fannin maganin ƙwayoyin halitta yana ci gaba da bunƙasa, inda maganin TIL yanzu ya bayyana a matsayin babban ci gaba a Maganin Ciwon dajiDuk da babban bege da aka dage a kan maganin CAR-T, tasirinsa ga ciwace-ciwacen da suka ƙunshi kashi 90% na ciwon daji, ya kasance kaɗan. Duk da haka, maganin TIL yana shirin canza wannan labarin.

Maganin TIL kwanan nan ya sami kulawa sosai lokacin da Lifileucel na Iovance Biotherapeutics ya sami amincewar FDA cikin sauri a ranar 16 ga Fabrairu don maganin melanoma wanda ya ci gaba bayan maganin rigakafi na PD-1. Amincewar Lifileucel ta nuna shi a matsayin maganin TIL na farko da ya isa kasuwa, wanda ke nuna wani sabon mataki a cikin maganin ƙwayoyin cuta wanda ya mayar da hankali kan ciwon daji mai ƙarfi.

Doguwar Hanya Zuwa Ga Nasara

Tafiyar maganin TIL ta ɗauki tsawon shekaru arba'in. Lymphocytes masu shiga cikin ƙwayar cuta (TILs) rukuni ne na ƙwayoyin rigakafi daban-daban da ake samu a cikin yanayin ciwon, ciki har da ƙwayoyin T, ƙwayoyin B, Nk Cells, macrophages, da ƙwayoyin hana ƙwayoyin cuta da suka samo asali daga myeloid. Waɗannan ƙwayoyin, waɗanda galibi suna da iyaka a adadi da aiki a cikin ciwace-ciwacen, ana iya girbe su, a faɗaɗa su a cikin dakin gwaje-gwaje, sannan a sake shigar da su cikin majiyyaci don kai hari da kuma lalata ƙwayoyin cutar kansa.

Ba kamar ƙwayoyin CAR-T ba, TILs ana samun su kai tsaye daga ƙari, wanda ke ba su damar gane nau'ikan antigens na ƙari da kuma samar da ingantattun bayanan shiga da aminci. Wannan hanyar ta nuna kyakkyawan sakamako, musamman wajen magance ciwon daji mai ƙarfi inda CAR-T ta sha wahala wajen cimma nasara.

Kawar da Kalubale

Lifileucel ya nuna sakamako mai ban mamaki na asibiti, yana ba wa marasa lafiya da ke fama da cutar melanoma waɗanda ke da ƙarancin zaɓuɓɓukan magani. A cikin gwajin asibiti na C-144-01, maganin ya cimma ƙimar amsawa ta gaskiya na 31%, tare da 42% na marasa lafiya da ke fuskantar martani na tsawon shekaru biyu. Duk da waɗannan nasarorin, hanyar zuwa ga ɗaukar yara yaɗuwa tana fuskantar manyan ƙalubale.

Kalubalen Masana'antu da Kasuwanci

Ɗaya daga cikin manyan ƙalubalen shine yanayin mutum ɗaya na Samfurin Tilion, wanda ke buƙatar dogon tsari mai rikitarwa na kera. Duk da cewa Iovance ya rage lokacin samarwa zuwa kimanin kwanaki 22, ana buƙatar ƙarin hanzari don biyan buƙatun marasa lafiya cikin sauri. Kamfanin yana da niyyar rage wannan lokacin zuwa kwanaki 16 ta hanyar ci gaba da ci gaba.

Kasuwanci yana kuma haifar da cikas. Babban farashin maganin da aka keɓance—wanda a halin yanzu farashinsa ya kai dala $515,000 ga Lifileucel, tare da ƙarin kuɗaɗen magani—yana iyakance ɗaukar matakin farko zuwa kasuwar Amurka. Domin cimma nasarar isa ga duniya da kuma dorewar tattalin arziki, kamfanoni dole ne su daidaita samarwa da rage farashi.

Sauƙaƙa tsarin magani don haɓaka ƙwarewar majiyyaci wani muhimmin abu ne. Maganin TIL ya ƙunshi matakai da yawa, gami da tattara ƙwayoyin ƙari, faɗaɗa ƙwayoyin halitta, da kuma lymphatic depletion, duk suna buƙatar cibiyoyin lafiya da ma'aikata na musamman. Gina hanyar sadarwa mai faɗi da inganci yana da mahimmanci don samun nasarar kasuwanci mai faɗi.

Makomar Alkawari

Idan aka yi la'akari da gaba, faɗaɗa maganin TIL zuwa wasu ƙwayoyin cuta masu ƙarfi har yanzu babban maƙasudi ne. Duk da cewa binciken da ake yi a yanzu ya fi mayar da hankali kan melanoma, ana ci gaba da ƙoƙarin gano ingancinsa a wasu cututtukan daji kamar ciwon huhu na ƙananan ƙwayoyin halitta. Fahimtar bambance-bambancen maganin TIL, gami da gano waɗanne ƙwayoyin T ne suka fi tasiri da kuma haɓaka magungunan haɗin gwiwa, zai zama mahimmanci.

Magungunan haɗin gwiwa, waɗanda suka haɗa TILs tare da jiyya na gargajiya kamar chemotherapy, radiation, immunotherapy, da alluran rigakafi, suna nuna yuwuwar haɓaka sakamakon magani da rage illolin da ke tattare da shi. Kamfanoni kamar Iovance sun riga sun fara binciken haɗin gwiwa da masu hana PD-1, da nufin inganta tasirin TIL da kuma yawan amsawar marasa lafiya.

Yayin da Lifileucel ke share fagen maganin TIL, fannin maganin ƙwayoyin halitta yana kan gaba wajen kawo sauyi a cikin maganin ciwon daji mai ƙarfi. Ƙoƙarin haɗin gwiwa da sabbin abubuwa daga kamfanonin magunguna za su tantance wanda zai jagoranci wannan sabon yanki. Fatan da maganin TIL ya kunna ya yi alƙawarin jawo ƙarin albarkatu da kulawa, yana haifar da ci gaba da kuma samar da sabon bege ga marasa lafiya a duk duniya.